Pathology: non squamous - mNSCLC - L1 - Wild Type (WT);
non squamous - mNSCLC - L1 - Wild Type (WT) | |||
IMpower-150 (ABCP vs BPC WT), 2018 | IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 | ||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 2 | T1 | T1 |
bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 |